Over the past four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity medicine. They are being taken by 1.5 million people in the UK and have already generated billions of dollars in revenue around the world.
But obesity expert Professor Carel Le Roux is particularly excited about the next big drug to hit the skinny-jab market: CagriSema.
